サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1758154

せん妄の世界市場

Delirium

出版日
ページ情報
英文 281 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
せん妄の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 281 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

せん妄の世界市場は2030年までに4,150万米ドルに達する見込み

2024年に3,270万米ドルと推定されるせん妄の世界市場は、2024年から2030年にかけてCAGR 4.0%で成長し、2030年には4,150万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである多動型は、CAGR 5.0％を記録し、分析期間終了時には2,460万米ドルに達すると予測されます。低活動型セグメントの成長率は、分析期間中CAGR 2.6％と推定されます。

米国市場は890万米ドルと推定、中国はCAGR 7.6％で成長予測

米国のせん妄市場は、2024年に890万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに850万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.2%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界のせん妄治療市場- 主要動向と促進要因まとめ

せん妄が急性期医療と高齢者医療で優先課題として浮上している理由とは？

せん妄は、突然の錯乱、見当識障害、意識レベルの変動を特徴とし、入院患者、特に高齢者、ICU患者、術後の患者における深刻な合併症として認識されつつあります。その影響は過小評価されがちであるが、せん妄は罹患率の増加、入院期間の延長、医療費の増加、長期的な認知機能低下のリスクの増大と関連しています。世界の人口が高齢化し、入院を必要とする慢性疾患の負担が増加するにつれ、せん妄の発生率はヘルスケアシステム全体で急増しています。

ヘルスケアプロバイダーは、特に老人病棟、手術回復室、集中治療室において、せん妄の早期発見と予防に重点を置くようになってきています。この病態は一般的に、感染症、多剤併用、代謝の不均衡、脆弱な患者の急激な環境変化など、複数の危険因子によって引き起こされます。せん妄は、もはや入院の必然的な部分としてではなく、予防可能で治療可能な症候群として捉えられており、効果的に管理するための薬理学的、非薬理学的、環境的戦略を組み合わせた集学的プロトコルの開発を促しています。

せん妄をより効果的に検出するために、診断・モニタリングツールはどのように進化しているか？

せん妄の早期かつ正確な発見は、その変動的な性質と認知症やうつ病との症状の重複により、依然として重要な課題です。そのため、Confusion Assessment Method（CAM）、Intensive Careせん妄Screening Checklist（ICDSC）、4ATスクリーニングツールなどの標準化されたスクリーニングツールが開発され、広く採用されるようになりました。これらの機器は現在、特に救急部、手術回復部、老人病棟などの臨床プロトコールに不可欠なものとなっています。持続的な患者モニタリング技術もICUに組み込まれ、せん妄の発症を知らせる認知機能の変動や生理的ストレス指標を追跡できるようになっています。

デジタルヘルスのイノベーションは診断分野にも進出しています。AIを活用した臨床判断支援システムや電子カルテ（EHR）と連動した警告システムは、リアルタイムの臨床データに基づいて高リスクの患者を特定するために導入されています。これらのプラットフォームは、投薬の見直し、環境の改善、水分補給のサポート、感覚の方向転換など、タイムリーな介入を可能にします。専門家以外の介護者向けに設計されたモバイルアプリやベッドサイド評価ツールも注目を集めており、在宅介護や長期介護施設における発見率の向上に役立っています。

せん妄の管理では、どのような治療戦略が有効か？

せん妄の管理は、予防、早期介入、根本的な誘因の最小化に重点を置いています。非薬理学的介入は、特に高齢者や術後の患者において、予防と治療の両面で最も重要なものです。これには、オリエンテーション戦略、睡眠衛生プロトコル、騒音軽減、疼痛管理、感覚遮断を軽減する視覚・聴覚補助具などが含まれます。病院高齢者生活プログラム（HELP）のような複合的ケアモデルは、せん妄の危険因子に体系的に対処し、患者の転帰を改善するために病院で採用されています。

薬理学的治療は通常、重度の興奮や自他へのリスクがある場合にのみ行われます。ハロペリドールのような抗精神病薬やクエチアピンやオランザピンのような非定型薬が用いられることもあるが、日常的な使用を支持するエビデンスはまだ様々です。睡眠覚醒周期を安定させるメラトニンやデクスメデトミジン、認知傷害を最小限に抑える神経保護薬などの代替薬物療法の調査も進行中です。基礎的な認知状態、併存疾患、薬剤感受性を考慮した個別化医療のアプローチは、せん妄ケアパスにおいてますます重要になってきています。

せん妄管理市場の拡大を促進する主な要因は？

せん妄管理市場の成長は、世界の高齢者人口の増加、慢性疾患患者の入院率の増加、せん妄のリスクと結果に関するヘルスケア専門家の意識の高まりなど、いくつかの要因によってもたらされます。病院が再入院率、ICU合併症、長期的な認知機能障害を減少させようとする中で、せん妄予防プロトコールは、全体的なクオリティケアのイニシアチブの一部として優先されています。国の医療機関や認定機関は、安全基準やパフォーマンス基準の一部として、せん妄評価を義務付けています。

EHRベースのスクリーニングツール、AIを活用した臨床判断支援、ウェアラブルな認知機能モニタリング機器によって、発見と管理プロセスが効率化されます。並行して、老年病専門医、神経科医、看護師、薬剤師を含む集学的ケアチームの拡大が、治療アプローチの標準化を強化しています。在宅療養の推進や、手術後やICU滞在後の遠隔モニタリングも、地域レベルのケアソリューションとの関連性を高めています。ヘルスケアシステムがより積極的に神経認知合併症に対処するようになるにつれ、せん妄の治療とモニタリングの領域は臨床的にも商業的にも大きく拡大していくでしょう。

セグメント

タイプ（過活動型、低活動型、混合型）;エンドユース（病院エンドユース、専門医療エンドユース、研究センターエンドユース）

調査対象企業の例

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Akorn Incorporated
  • Alkermes plc
  • Apotex Inc.
  • BioXcel Therapeutics, Inc.
  • Ceribell, Inc.
  • Delix Therapeutics
  • Eleusis Ltd.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mind Medicine（MindMed）Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36679

Global Delirium Market to Reach US$41.5 Million by 2030

The global market for Delirium estimated at US$32.7 Million in the year 2024, is expected to reach US$41.5 Million by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Hyperactive Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$24.6 Million by the end of the analysis period. Growth in the Hypoactive Type segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.9 Million While China is Forecast to Grow at 7.6% CAGR

The Delirium market in the U.S. is estimated at US$8.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.5 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Delirium Treatment Market - Key Trends & Drivers Summarized

Why Is Delirium Emerging as a Priority Concern in Acute and Elderly Care?

Delirium, characterized by a sudden onset of confusion, disorientation, and fluctuating levels of consciousness, is increasingly recognized as a serious complication in hospitalized patients-especially among the elderly, ICU patients, and post-operative individuals. Its impact is often underestimated, yet delirium is associated with increased morbidity, prolonged hospital stays, higher healthcare costs, and a greater risk of long-term cognitive decline. As global populations age and the burden of chronic illnesses requiring hospitalization rises, the incidence of delirium is surging across healthcare systems.

Healthcare providers are placing growing emphasis on early identification and prevention of delirium, especially in geriatric wards, surgical recovery units, and intensive care settings. The condition is commonly triggered by multiple risk factors such as infections, polypharmacy, metabolic imbalances, and sudden environmental changes in vulnerable patients. Delirium is no longer viewed as an inevitable part of hospitalization but as a preventable and treatable syndrome, prompting the development of multidisciplinary protocols that combine pharmacological, non-pharmacological, and environmental strategies to manage it effectively.

How Are Diagnostic and Monitoring Tools Evolving to Detect Delirium More Effectively?

Early and accurate detection of delirium remains a critical challenge due to its fluctuating nature and symptom overlap with dementia and depression. This has led to the development and widespread adoption of standardized screening tools such as the Confusion Assessment Method (CAM), the Intensive Care Delirium Screening Checklist (ICDSC), and the 4AT screening tool. These instruments are now integral to clinical protocols, especially in emergency departments, surgical recovery, and geriatric care units. Continuous patient monitoring technologies are also being integrated into ICU settings to track cognitive fluctuations and physiological stress indicators that may signal the onset of delirium.

Digital health innovations are also entering the diagnostic space. AI-powered clinical decision support systems and electronic health record (EHR)-linked alert systems are being deployed to identify high-risk patients based on real-time clinical data. These platforms enable timely interventions such as medication review, environmental modification, hydration support, and sensory reorientation. Mobile apps and bedside assessment tools designed for non-specialist caregivers are also gaining attention, helping improve detection rates in home care and long-term care facilities.

What Therapeutic Strategies Are Gaining Ground in the Management of Delirium?

Management of delirium emphasizes prevention, early intervention, and minimizing underlying triggers. Non-pharmacological interventions remain the gold standard for both prevention and treatment, especially in elderly and post-operative patients. These include orientation strategies, sleep hygiene protocols, noise reduction, pain management, and vision/hearing aids to reduce sensory deprivation. Multicomponent care models such as the Hospital Elder Life Program (HELP) are being adopted by hospitals to systematically address delirium risk factors and improve patient outcomes.

Pharmacological treatments are typically reserved for cases of severe agitation or risk to self and others. Antipsychotics such as haloperidol and atypical agents like quetiapine and olanzapine are sometimes used, although evidence supporting their routine use remains mixed. Research into alternative pharmacotherapies is ongoing, including melatonin and dexmedetomidine for sleep-wake cycle stabilization and neuroprotective agents to minimize cognitive injury. Personalized medicine approaches that account for underlying cognitive status, co-morbidities, and drug sensitivity are becoming increasingly important in delirium care pathways.

What Are the Main Forces Driving the Expansion of the Delirium Management Market?

The growth in the delirium management market is driven by several factors, including the rising global geriatric population, increased hospitalization rates among patients with chronic conditions, and growing awareness among healthcare professionals about the risks and consequences of delirium. As hospitals seek to reduce readmission rates, ICU complications, and long-term cognitive impairment, delirium prevention protocols are being prioritized as part of overall quality care initiatives. National health agencies and accreditation bodies are mandating delirium assessment as part of safety and performance standards.

Technological integration is another growth catalyst, with EHR-based screening tools, AI-enabled clinical decision support, and wearable cognitive monitoring devices streamlining the detection and management process. In parallel, the expansion of multidisciplinary care teams involving geriatricians, neurologists, nurses, and pharmacists is enhancing the standardization of treatment approaches. The push for home-based recovery and remote monitoring post-surgery or ICU stay is also increasing the relevance of community-level delirium care solutions. As healthcare systems become more proactive in addressing neurocognitive complications, the delirium treatment and monitoring landscape is set for significant clinical and commercial expansion

SCOPE OF STUDY:

The report analyzes the Delirium market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Hyperactive Type, Hypoactive Type, Mixed Type); End-Use (Hospitals End-Use, Specialty Care End-Use, Research Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Akorn Incorporated
  • Alkermes plc
  • Apotex Inc.
  • BioXcel Therapeutics, Inc.
  • Ceribell, Inc.
  • Delix Therapeutics
  • Eleusis Ltd.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mind Medicine (MindMed) Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Delirium - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Hospitalization of Elderly Patients Propels Incidence and Diagnosis of Delirium
    • Increased Awareness Among Healthcare Providers Strengthens Early Detection and Clinical Management
    • Expansion of Geriatric Healthcare Infrastructure Throws the Spotlight on Acute Cognitive Impairments
    • Adoption of Screening Tools and Assessment Protocols Enhances Diagnostic Accuracy in ICU Settings
    • Growth in Post-Surgical and Trauma-Related Hospital Admissions Fuels Acute Delirium Cases
    • Use of Benzodiazepines and Polypharmacy in Elderly Populations Drives Risk of Delirium Onset
    • Rising Demand for Non-Pharmacological Interventions Promotes Multidisciplinary Care Programs
    • Regulatory Emphasis on Patient Safety and Cognitive Monitoring Supports ICU Delirium Protocols
    • Integration With Hospital EMR and Alert Systems Enhances Monitoring of High-Risk Patients
    • Increased Research on Delirium-Associated Mortality Promotes Investment in Preventive Strategies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Delirium Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Delirium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Delirium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hyperactive Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hyperactive Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hyperactive Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hypoactive Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hypoactive Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hypoactive Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mixed Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mixed Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Mixed Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Care End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Care End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Care End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Research Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Delirium by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Delirium by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Delirium by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Delirium by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Delirium by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Delirium by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Delirium by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Delirium by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION